Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Verona Pharma Plc (VRNA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Verona Pharma Plc. Table 2 shows the detailed insider transactions. This company's CIK number is 1657312.
Total stock buying since 2021: $7,171,126.
Total stock sales since 2021: $374,619,560.
Total stock option exercises since 2021: $1,457,380.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 4,179,224 | $42,226,191 | 3,535,472 | $1,457,380 |
| 2024 | 117,240 | $490,593 | 5,907,696 | $25,416,005 | 0 | $0 |
| 2023 | 193,736 | $378,133 | 4,343,706 | $29,161,716 | 283,800 | $0 |
| 2022 | 4,800,000 | $6,302,400 | 14,115,376 | $277,491,149 | 0 | $0 |
| 2021 | 0 | $0 | 373,064 | $324,499 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 540,584 | $7,105,431 | 843,168 | $0 |
| 2025-07 | 0 | $0 | 0 | $0 | 631,152 | $0 |
| 2025-06 | 0 | $0 | 880,000 | $10,042,800 | 80,000 | $160,880 |
| 2025-05 | 0 | $0 | 2,418,200 | $22,071,849 | 870,000 | $597,800 |
| 2025-04 | 0 | $0 | 261,176 | $2,344,178 | 651,152 | $22,040 |
| 2025-03 | 0 | $0 | 79,264 | $661,933 | 0 | $0 |
| 2025-02 | 0 | $0 | 0 | $0 | 460,000 | $676,660 |
| 2024-12 | 0 | $0 | 1,757,432 | $8,798,152 | 0 | $0 |
| 2024-11 | 81,240 | $387,273 | 748,472 | $3,553,579 | 0 | $0 |
| 2024-10 | 0 | $0 | 1,329,296 | $5,823,830 | 0 | $0 |
| 2024-09 | 0 | $0 | 1,200,000 | $4,508,400 | 0 | $0 |
| 2024-08 | 36,000 | $103,320 | 800,000 | $2,580,492 | 0 | $0 |
| 2024-05 | 0 | $0 | 36,248 | $71,046 | 0 | $0 |
| 2024-02 | 0 | $0 | 36,248 | $80,506 | 0 | $0 |
| 2023-11 | 193,736 | $378,133 | 58,752 | $112,803 | 0 | $0 |
| 2023-08 | 0 | $0 | 1,104,704 | $2,833,953 | 0 | $0 |
| 2023-05 | 0 | $0 | 2,063,442 | $23,354,494 | 0 | $0 |
| 2023-02 | 0 | $0 | 1,116,808 | $2,860,466 | 0 | $0 |
| 2023-01 | 0 | $0 | 0 | $0 | 283,800 | $0 |
| 2022-12 | 0 | $0 | 12,519,728 | $275,148,710 | 0 | $0 |
| 2022-08 | 4,800,000 | $6,302,400 | 1,274,824 | $2,152,461 | 0 | $0 |
| 2022-05 | 0 | $0 | 74,168 | $36,670 | 0 | $0 |
| 2022-04 | 0 | $0 | 172,520 | $98,568 | 0 | $0 |
| 2022-02 | 0 | $0 | 74,136 | $54,740 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-01 | Fisher Andrew (General Counsel) | Sale | 9,584 | 13.14 | 125,972 |
| 2025-08-01 | Fisher Andrew (General Counsel) | Option Ex | 20,888 | .00 | 0 |
| 2025-08-01 | Austwick Michael | Sale | 11,288 | 13.14 | 148,369 |
| 2025-08-01 | Austwick Michael | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Brady James Aloysius | Sale | 824 | 13.14 | 10,830 |
| 2025-08-01 | Brady James Aloysius | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Deschamps Lisa | Sale | 9,464 | 13.14 | 124,394 |
| 2025-08-01 | Deschamps Lisa | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 58,336 | 13.14 | 766,768 |
| 2025-08-01 | Rickard Kathleen A. (Chief Medical Officer) | Option Ex | 70,888 | .00 | 0 |
| 2025-08-01 | Cunningham Kenneth | Sale | 10,808 | 13.14 | 142,060 |
| 2025-08-01 | Cunningham Kenneth | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Ullman Anders | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Ackermann Christina | Sale | 1,808 | 13.14 | 23,764 |
| 2025-08-01 | Ackermann Christina | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Edwards Martin | Sale | 10,808 | 13.14 | 142,060 |
| 2025-08-01 | Edwards Martin | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Zaccardelli David (President and CEO) | Sale | 208,912 | 13.14 | 2,745,939 |
| 2025-08-01 | Zaccardelli David (President and CEO) | Option Ex | 255,696 | .00 | 0 |
| 2025-08-01 | Hahn Mark W (Chief Financial Officer) | Sale | 208,912 | 13.14 | 2,745,939 |
| 2025-08-01 | Hahn Mark W (Chief Financial Officer) | Option Ex | 255,696 | .00 | 0 |
| 2025-08-01 | Sinha Vikas | Sale | 4,328 | 13.14 | 56,887 |
| 2025-08-01 | Sinha Vikas | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Shah Mahendra | Sale | 3,608 | 13.14 | 47,423 |
| 2025-08-01 | Shah Mahendra | Option Ex | 24,000 | .00 | 0 |
| 2025-08-01 | Ebsworth David R | Sale | 1,904 | 13.14 | 25,026 |
| 2025-08-01 | Ebsworth David R | Option Ex | 24,000 | .00 | 0 |
| 2025-07-07 | Fisher Andrew (General Counsel) | Option Ex | 86,064 | .00 | 0 |
| 2025-07-07 | Rickard Kathleen A. (Chief Medical Officer) | Option Ex | 86,064 | .00 | 0 |
| 2025-07-07 | Zaccardelli David (President and CEO) | Option Ex | 229,512 | .00 | 0 |
| 2025-07-07 | Hahn Mark W (Chief Financial Officer) | Option Ex | 229,512 | .00 | 0 |
| 2025-06-16 | Fisher Andrew (General Counsel) | Sale | 80,000 | 11.53 | 922,000 |
| 2025-06-16 | Fisher Andrew (General Counsel) | Option Ex | 80,000 | 2.01 | 160,880 |
| 2025-06-11 | Zaccardelli David (President and CEO) | Sale | 400,000 | 11.40 | 4,560,400 |
| 2025-06-11 | Hahn Mark W (Chief Financial Officer) | Sale | 400,000 | 11.40 | 4,560,400 |
| 2025-05-29 | Zaccardelli David (President and CEO) | Sale | 208,696 | 9.33 | 1,947,551 |
| 2025-05-29 | Hahn Mark W (Chief Financial Officer) | Sale | 204,864 | 9.33 | 1,911,585 |
| 2025-05-28 | Zaccardelli David (President and CEO) | Sale | 157,704 | 9.30 | 1,466,804 |
| 2025-05-28 | Hahn Mark W (Chief Financial Officer) | Sale | 162,704 | 9.30 | 1,513,309 |
| 2025-05-27 | Zaccardelli David (President and CEO) | Sale | 33,600 | 9.53 | 320,174 |
| 2025-05-27 | Hahn Mark W (Chief Financial Officer) | Sale | 32,432 | 9.53 | 308,979 |
| 2025-05-20 | Sinha Vikas | Sale | 160,000 | 9.39 | 1,502,880 |
| 2025-05-20 | Sinha Vikas | Option Ex | 160,000 | .50 | 80,640 |
| 2025-05-15 | Fisher Andrew (General Counsel) | Sale | 80,000 | 8.57 | 685,600 |
| 2025-05-15 | Fisher Andrew (General Counsel) | Option Ex | 80,000 | 2.11 | 169,040 |
| 2025-05-14 | Ackermann Christina | Sale | 40,000 | 8.44 | 337,600 |
| 2025-05-14 | Ackermann Christina | Option Ex | 40,000 | 1.93 | 77,360 |
| 2025-05-06 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 114,984 | 8.82 | 1,014,388 |
| 2025-05-02 | Zaccardelli David (President and CEO) | Sale | 400,000 | 9.09 | 3,637,599 |
| 2025-05-02 | Hahn Mark W (Chief Financial Officer) | Sale | 400,000 | 9.09 | 3,637,599 |
| 2025-05-01 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 49,200 | 8.95 | 440,339 |
| 2025-05-01 | Rickard Kathleen A. (Chief Medical Officer) | Option Ex | 50,000 | .00 | 0 |
| 2025-05-01 | Zaccardelli David (President and CEO) | Sale | 187,008 | 8.95 | 1,673,721 |
| 2025-05-01 | Zaccardelli David (President and CEO) | Option Ex | 200,000 | .00 | 0 |
| 2025-05-01 | Hahn Mark W (Chief Financial Officer) | Sale | 187,008 | 8.95 | 1,673,721 |
| 2025-05-01 | Hahn Mark W (Chief Financial Officer) | Option Ex | 200,000 | .00 | 0 |
| 2025-05-01 | Ebsworth David R | Option Ex | 140,000 | 1.93 | 270,760 |
| 2025-04-29 | Fisher Andrew (General Counsel) | Sale | 26,072 | 8.98 | 234,126 |
| 2025-04-29 | Fisher Andrew (General Counsel) | Option Ex | 86,064 | .00 | 0 |
| 2025-04-29 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 34,384 | 8.98 | 308,768 |
| 2025-04-29 | Rickard Kathleen A. (Chief Medical Officer) | Option Ex | 86,064 | .00 | 0 |
| 2025-04-29 | Zaccardelli David (President and CEO) | Sale | 90,360 | 8.98 | 811,432 |
| 2025-04-29 | Zaccardelli David (President and CEO) | Option Ex | 229,512 | .00 | 0 |
| 2025-04-29 | Hahn Mark W (Chief Financial Officer) | Sale | 90,360 | 8.98 | 811,432 |
| 2025-04-29 | Hahn Mark W (Chief Financial Officer) | Option Ex | 229,512 | .00 | 0 |
| 2025-04-29 | Sinha Vikas | Sale | 20,000 | 8.92 | 178,420 |
| 2025-04-29 | Sinha Vikas | Option Ex | 20,000 | 1.10 | 22,040 |
| 2025-03-12 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 79,264 | 8.35 | 661,933 |
| 2025-02-26 | Ebsworth David R | Option Ex | 460,000 | 1.47 | 676,660 |
| 2024-12-06 | Zaccardelli David (President and CEO) | Sale | 162,800 | 5.01 | 815,465 |
| 2024-12-06 | Hahn Mark W (Chief Financial Officer) | Sale | 183,728 | 5.01 | 920,293 |
| 2024-12-05 | Zaccardelli David (President and CEO) | Sale | 640,264 | 5.01 | 3,205,161 |
| 2024-12-05 | Hahn Mark W (Chief Financial Officer) | Sale | 640,048 | 5.01 | 3,204,080 |
| 2024-12-04 | Zaccardelli David (President and CEO) | Sale | 67,608 | 5.00 | 338,175 |
| 2024-12-04 | Hahn Mark W (Chief Financial Officer) | Sale | 58,184 | 5.00 | 290,978 |
| 2024-12-02 | Zaccardelli David (President and CEO) | Sale | 3,200 | 5.00 | 16,000 |
| 2024-12-02 | Hahn Mark W (Chief Financial Officer) | Sale | 1,600 | 5.00 | 8,000 |
| 2024-11-29 | Zaccardelli David (President and CEO) | Sale | 98,888 | 5.01 | 495,033 |
| 2024-11-29 | Hahn Mark W (Chief Financial Officer) | Sale | 98,704 | 5.01 | 494,112 |
| 2024-11-27 | Zaccardelli David (President and CEO) | Sale | 23,240 | 5.00 | 116,200 |
| 2024-11-27 | Hahn Mark W (Chief Financial Officer) | Sale | 12,936 | 5.00 | 64,680 |
| 2024-11-26 | Hahn Mark W (Chief Financial Officer) | Sale | 800 | 5.00 | 4,000 |
| 2024-11-25 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 240,000 | 4.90 | 1,176,480 |
| 2024-11-25 | Zaccardelli David (President and CEO) | Sale | 1,600 | 5.00 | 8,000 |
| 2024-11-25 | Hahn Mark W (Chief Financial Officer) | Sale | 1,600 | 5.00 | 8,000 |
| 2024-11-06 | Ackermann Christina | Buy | 41,880 | 4.74 | 198,385 |
| 2024-11-06 | Ebsworth David R | Buy | 39,360 | 4.80 | 188,888 |
| 2024-11-04 | Zaccardelli David (President and CEO) | Sale | 94,144 | 4.39 | 413,480 |
| 2024-11-04 | Hahn Mark W (Chief Financial Officer) | Sale | 80,784 | 4.39 | 354,480 |
| 2024-11-01 | Zaccardelli David (President and CEO) | Sale | 46,888 | 4.38 | 205,181 |
| 2024-11-01 | Hahn Mark W (Chief Financial Officer) | Sale | 48,888 | 4.38 | 213,933 |
| 2024-10-25 | Zaccardelli David (President and CEO) | Sale | 4,800 | 4.38 | 21,004 |
| 2024-10-25 | Hahn Mark W (Chief Financial Officer) | Sale | 3,200 | 4.38 | 14,000 |
| 2024-10-24 | Zaccardelli David (President and CEO) | Sale | 140,000 | 4.38 | 612,780 |
| 2024-10-24 | Hahn Mark W (Chief Financial Officer) | Sale | 141,360 | 4.38 | 618,732 |
| 2024-10-23 | Zaccardelli David (President and CEO) | Sale | 16 | 4.38 | 70 |
| 2024-10-22 | Zaccardelli David (President and CEO) | Sale | 157,912 | 4.39 | 692,759 |
| 2024-10-22 | Hahn Mark W (Chief Financial Officer) | Sale | 159,344 | 4.38 | 698,723 |
| 2024-10-21 | Zaccardelli David (President and CEO) | Sale | 110,456 | 4.38 | 483,797 |
| 2024-10-21 | Hahn Mark W (Chief Financial Officer) | Sale | 116,696 | 4.38 | 511,128 |
| 2024-10-18 | Zaccardelli David (President and CEO) | Sale | 245,784 | 4.38 | 1,076,779 |
| 2024-10-18 | Hahn Mark W (Chief Financial Officer) | Sale | 249,728 | 4.38 | 1,094,058 |
| 2024-09-11 | Zaccardelli David (President and CEO) | Sale | 600,000 | 3.76 | 2,254,200 |
| 2024-09-11 | Hahn Mark W (Chief Financial Officer) | Sale | 600,000 | 3.76 | 2,254,200 |
| 2024-08-13 | Zaccardelli David (President and CEO) | Sale | 398,400 | 3.23 | 1,285,238 |
| 2024-08-13 | Hahn Mark W (Chief Financial Officer) | Sale | 398,400 | 3.23 | 1,285,238 |
| 2024-08-12 | Zaccardelli David (President and CEO) | Sale | 1,600 | 3.13 | 5,008 |
| 2024-08-12 | Hahn Mark W (Chief Financial Officer) | Sale | 1,600 | 3.13 | 5,008 |
| 2024-08-12 | Ebsworth David R | Buy | 36,000 | 2.87 | 103,320 |
| 2024-05-03 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 36,248 | 1.96 | 71,046 |
| 2024-02-05 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 36,248 | 2.22 | 80,506 |
| 2023-11-20 | Edwards Martin | Buy | 33,736 | 1.84 | 61,973 |
| 2023-11-06 | Ebsworth David R | Buy | 160,000 | 1.98 | 316,160 |
| 2023-11-03 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 58,752 | 1.92 | 112,803 |
| 2023-08-07 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 1,600 | 2.47 | 3,948 |
| 2023-08-07 | Poll Claire (General Counsel) | Sale | 1,512 | 2.47 | 3,731 |
| 2023-08-07 | Zaccardelli David (President and CEO) | Sale | 8,616 | 2.47 | 21,264 |
| 2023-08-07 | Hahn Mark W (Chief Financial Officer) | Sale | 8,616 | 2.47 | 21,264 |
| 2023-08-04 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 27,944 | 2.50 | 69,832 |
| 2023-08-04 | Poll Claire (General Counsel) | Sale | 26,352 | 2.50 | 65,853 |
| 2023-08-04 | Zaccardelli David (President and CEO) | Sale | 150,000 | 2.50 | 374,850 |
| 2023-08-04 | Hahn Mark W (Chief Financial Officer) | Sale | 150,000 | 2.50 | 374,850 |
| 2023-08-03 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 50,600 | 2.54 | 128,777 |
| 2023-08-03 | Poll Claire (General Counsel) | Sale | 20,608 | 2.54 | 52,323 |
| 2023-08-03 | Zaccardelli David (President and CEO) | Sale | 117,272 | 2.54 | 297,753 |
| 2023-08-03 | Hahn Mark W (Chief Financial Officer) | Sale | 117,272 | 2.54 | 297,753 |
| 2023-08-02 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 13,728 | 2.59 | 35,596 |
| 2023-08-02 | Poll Claire (General Counsel) | Sale | 12,944 | 2.59 | 33,563 |
| 2023-08-02 | Zaccardelli David (President and CEO) | Sale | 73,704 | 2.59 | 191,114 |
| 2023-08-02 | Hahn Mark W (Chief Financial Officer) | Sale | 73,704 | 2.59 | 191,114 |
| 2023-08-01 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 19,736 | 2.68 | 52,872 |
| 2023-08-01 | Poll Claire (General Counsel) | Sale | 18,608 | 2.68 | 49,850 |
| 2023-08-01 | Zaccardelli David (President and CEO) | Sale | 105,944 | 2.68 | 283,823 |
| 2023-08-01 | Hahn Mark W (Chief Financial Officer) | Sale | 105,944 | 2.68 | 283,823 |
| 2023-05-15 | Orbimed Capital Gp Vi Llc | Sale | 359,713 | 20.98 | 7,546,778 |
| 2023-05-15 | Gupta Rishi | Sale | 359,713 | 20.98 | 7,546,778 |
| 2023-05-12 | Orbimed Capital Gp Vi Llc | Sale | 43,200 | 21.64 | 934,848 |
| 2023-05-12 | Gupta Rishi | Sale | 43,200 | 21.64 | 934,848 |
| 2023-05-11 | Orbimed Capital Gp Vi Llc | Sale | 80,000 | 22.26 | 1,780,800 |
| 2023-05-11 | Gupta Rishi | Sale | 80,000 | 22.26 | 1,780,800 |
| 2023-05-03 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 28,752 | 2.65 | 76,250 |
| 2023-05-01 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 77,424 | 2.58 | 199,444 |
| 2023-05-01 | Poll Claire (General Counsel) | Sale | 80,376 | 2.58 | 207,048 |
| 2023-05-01 | Zaccardelli David (President and CEO) | Sale | 455,536 | 2.58 | 1,173,460 |
| 2023-05-01 | Hahn Mark W (Chief Financial Officer) | Sale | 455,528 | 2.58 | 1,173,440 |
| 2023-02-02 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 28,752 | 2.53 | 72,685 |
| 2023-02-01 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 89,960 | 2.56 | 230,027 |
| 2023-02-01 | Poll Claire (General Counsel) | Sale | 152,000 | 2.59 | 394,288 |
| 2023-02-01 | Zaccardelli David (President and CEO) | Sale | 432,928 | 2.56 | 1,106,996 |
| 2023-02-01 | Hahn Mark W (Chief Financial Officer) | Sale | 413,168 | 2.56 | 1,056,470 |
| 2023-01-20 | Rickard Kathleen A. (Chief Medical Officer) | Option Ex | 105,000 | .00 | 0 |
| 2023-01-20 | Poll Claire (General Counsel) | Option Ex | 178,800 | .00 | 0 |
| 2022-12-23 | Orbimed Capital Gp Vi Llc | Sale | 2,170,368 | 23.20 | 50,359,048 |
| 2022-12-23 | Gupta Rishi | Sale | 2,170,368 | 23.20 | 50,359,048 |
| 2022-12-22 | Poll Claire (General Counsel) | Sale | 240,000 | 2.69 | 646,080 |
| 2022-12-22 | Orbimed Capital Gp Vi Llc | Sale | 3,969,496 | 21.89 | 86,892,267 |
| 2022-12-22 | Gupta Rishi | Sale | 3,969,496 | 21.89 | 86,892,267 |
| 2022-08-15 | Blavatnik Len (10% Owner) | Buy | 4,800,000 | 1.31 | 6,302,400 |
| 2022-08-09 | Zaccardelli David (President and CEO) | Sale | 600,000 | 1.75 | 1,050,000 |
| 2022-08-09 | Hahn Mark W (Chief Financial Officer) | Sale | 600,000 | 1.75 | 1,050,000 |
| 2022-08-02 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 28,752 | .70 | 20,212 |
| 2022-08-01 | Zaccardelli David (President and CEO) | Sale | 32,904 | .70 | 23,032 |
| 2022-08-01 | Hahn Mark W (Chief Financial Officer) | Sale | 13,168 | .70 | 9,217 |
| 2022-05-03 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 28,752 | .49 | 14,145 |
| 2022-05-03 | Zaccardelli David (President and CEO) | Sale | 32,904 | .50 | 16,320 |
| 2022-05-03 | Hahn Mark W (Chief Financial Officer) | Sale | 12,512 | .50 | 6,205 |
| 2022-04-11 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 59,720 | .54 | 32,129 |
| 2022-04-08 | Rickard Kathleen A. (Chief Medical Officer) | Sale | 112,800 | .59 | 66,439 |
| 2022-02-03 | Zaccardelli David (President and CEO) | Sale | 52,056 | .73 | 37,792 |
| 2022-02-02 | Hahn Mark W (Chief Financial Officer) | Sale | 10,416 | .76 | 7,874 |
| 2022-02-01 | Deschamps Lisa | Sale | 11,664 | .78 | 9,074 |
| 2021-11-02 | Deschamps Lisa | Sale | 11,672 | .66 | 7,691 |
| 2021-11-02 | Zaccardelli David (President and CEO) | Sale | 52,056 | .64 | 33,367 |
| 2021-11-02 | Hahn Mark W (Chief Financial Officer) | Sale | 10,416 | .65 | 6,718 |
| 2021-08-04 | Zaccardelli David (President and CEO) | Sale | 18,400 | .74 | 13,671 |
| 2021-08-03 | Zaccardelli David (President and CEO) | Sale | 33,656 | .76 | 25,485 |
| 2021-08-02 | Hahn Mark W (Chief Financial Officer) | Sale | 10,416 | .77 | 7,989 |
| 2021-05-04 | Deschamps Lisa | Sale | 10,680 | .84 | 8,971 |
| 2021-05-04 | Cunningham Kenneth | Sale | 13,112 | .84 | 11,014 |
| 2021-05-04 | Ullman Anders | Sale | 12,056 | .84 | 10,127 |
| 2021-05-04 | Sinha Vikas | Sale | 10,016 | .84 | 8,413 |
| 2021-05-04 | Shah Mahendra | Sale | 10,680 | .84 | 8,971 |
| 2021-05-04 | Ebsworth David R | Sale | 11,184 | .84 | 9,394 |
| 2021-05-03 | Hahn Mark W (Chief Financial Officer) | Sale | 10,416 | .87 | 9,093 |
| 2021-03-01 | Zaccardelli David (President and CEO) | Sale | 43,392 | 1.14 | 49,640 |
| 2021-03-01 | Hahn Mark W (Chief Financial Officer) | Sale | 26,728 | 1.14 | 30,576 |
| 2021-02-01 | Cunningham Kenneth | Sale | 13,104 | .99 | 13,025 |
| 2021-02-01 | Ullman Anders | Sale | 10,800 | .99 | 10,735 |
| 2021-02-01 | Edwards Martin | Sale | 13,688 | .99 | 13,605 |
| 2021-02-01 | Sinha Vikas | Sale | 10,224 | .99 | 10,162 |
| 2021-02-01 | Shah Mahendra | Sale | 10,800 | .99 | 10,735 |
| 2021-02-01 | Ebsworth David R | Sale | 11,912 | .99 | 11,840 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRNA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Verona Pharma Plc (symbol VRNA, CIK number 1657312) see the Securities and Exchange Commission (SEC) website.